Cansortium Inc.

CNSX:TIUM.U Stock Report

Market Cap: US$28.7m

Cansortium Valuation

Is TIUM.U undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TIUM.U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TIUM.U ($0.09) is trading above our estimate of fair value ($0.04)

Significantly Below Fair Value: TIUM.U is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TIUM.U?

Key metric: As TIUM.U is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TIUM.U. This is calculated by dividing TIUM.U's market cap by their current revenue.
What is TIUM.U's PS Ratio?
PS Ratio0.3x
SalesUS$103.30m
Market CapUS$28.70m

Price to Sales Ratio vs Peers

How does TIUM.U's PS Ratio compare to its peers?

The above table shows the PS ratio for TIUM.U vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.4x
LABS MediPharm Labs
0.7x18.1%CA$28.8m
ACRG.A.U Acreage Holdings
0.08xn/aUS$26.8m
DB Decibel Cannabis
0.3x11.8%CA$28.8m
MDP Medexus Pharmaceuticals
0.4x6.5%CA$52.0m
TIUM.U Cansortium
0.3xn/aUS$28.7m

Price-To-Sales vs Peers: TIUM.U is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.4x).

Price to Sales Ratio vs Industry

How does TIUM.U's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.2x2.6%US$82.27m
ACRG.A.U Acreage Holdings
0.08xn/aUS$26.82m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
IMCC IM Cannabis
0.2x24.8%US$7.96m
TIUM.U 0.3xIndustry Avg. 0.7xNo. of Companies23PS012345+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TIUM.U is good value based on its Price-To-Sales Ratio (0.3x) compared to the Canadian Pharmaceuticals industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is TIUM.U's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TIUM.U PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TIUM.U's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7D

7.6%

1Y

-44.2%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

7D

5.4%

1Y

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

7D

-12.8%

1Y

-60.6%